FDA OKs Medtronic's third HF (heart failure) device:
This article was originally published in Clinica
Executive Summary
The US FDA has given Medtronic the go-ahead to market its third cardiac resynchronisation therapy (CRT) product for treating heart failure (HF). The InSync III cardiac resynchronisation therapy system features a new function called "sequential biventricular pacing", which allows physicians to independently programme and control the sequence of contractions of both ventricles of the heart. The ability to adjust the pacing sequence of the ventricles can help doctor's improve the heart's performance, Medtronic says.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.